Can I Take Vitamin D with Praluent (Alirocumab)?

Why This Question Comes Up

Patients prescribed Praluent (alirocumab) for familial hypercholesterolemia or atherosclerotic cardiovascular disease (ASCVD) often already take multiple medications. Adding a vitamin D supplement raises a reasonable concern: could the supplement blunt the drug's LDL-lowering effect, or could the drug interfere with vitamin D metabolism?

The Overlap Between Cardiovascular Disease and Vitamin D Deficiency

The concern is common because the populations overlap. A National Health and Nutrition Examination Survey (NHANES) analysis found that 41.6% of U.S. Adults have serum 25-hydroxyvitamin D levels below 20 ng/mL, the threshold the Endocrine Society defines as deficient [1]. Rates climb higher among adults over 65, those with obesity, and individuals with limited sun exposure. These same groups carry elevated cardiovascular risk and are the patients most likely to receive a PCSK9 inhibitor like alirocumab.

Why Patients Worry About Supplement Interactions

Certain cholesterol-lowering drugs do interact with supplements. Bile acid sequestrants (cholestyramine, colesevelam) can reduce fat-soluble vitamin absorption, including vitamin D, by 30% or more when taken simultaneously [2]. Patients who have used these older agents may assume the same caution applies to alirocumab. It does not.

How Alirocumab Works (and Why Vitamin D Cannot Interfere)

Alirocumab is a fully human monoclonal antibody that binds proprotein convertase subtilisin/kexin type 9 (PCSK9). By blocking PCSK9, the drug prevents degradation of LDL receptors on hepatocyte surfaces, allowing more circulating LDL-C to be cleared from the blood. The ODYSSEY LONG TERM trial (N=2,341) demonstrated a mean LDL-C reduction of 54.7% at 24 weeks versus placebo in patients already on maximally tolerated statin therapy [3].

Proteolytic Clearance, Not Hepatic Metabolism

Small-molecule drugs are processed through cytochrome P450 (CYP) enzymes in the liver. That is where most drug-drug and drug-supplement interactions occur. Alirocumab bypasses this pathway entirely. As a large-molecular-weight protein (~146 kDa), it is cleared through target-mediated disposition (binding to PCSK9) and nonspecific proteolytic degradation via the reticuloendothelial system [4]. The FDA prescribing information for Praluent does not list any CYP-mediated interactions [5].

Vitamin D's Metabolic Route

Vitamin D3 (cholecalciferol) is hydroxylated first in the liver by CYP2R1 to 25(OH)D, then in the kidney by CYP27B1 to the active 1,25-dihydroxyvitamin D. Because alirocumab never touches the CYP system, it cannot inhibit or induce these enzymes. The two compounds occupy entirely separate pharmacokinetic lanes.

What the Evidence Shows

No randomized controlled trial has been designed specifically to test a vitamin D and alirocumab interaction. That absence itself is informative. Regulatory agencies and drug interaction databases (Natural Medicines Comprehensive Database, Lexicomp, Clinical Pharmacology) do not flag a vitamin D/alirocumab interaction. The mechanistic rationale explains why: there is no shared transporter, enzyme, or receptor target.

Observational Data on Vitamin D and Lipid Levels

A meta-analysis of 41 RCTs (N=3,434) published in the Journal of Clinical Endocrinology & Metabolism found that vitamin D supplementation had no significant effect on total cholesterol, LDL-C, or HDL-C in the pooled analysis [6]. Vitamin D does not raise LDL-C and therefore cannot pharmacodynamically oppose alirocumab's mechanism.

The VITAL Trial and Cardiovascular Outcomes

The VITAL trial (N=25,871) randomized adults to 2,000 IU/day of vitamin D3 versus placebo over a median 5.3 years. Vitamin D supplementation did not significantly reduce major cardiovascular events (HR 0.97, 95% CI 0.85 to 1.12) [7]. This confirms that vitamin D supplementation neither helps nor harms cardiovascular outcomes through a lipid pathway, reinforcing the lack of pharmacodynamic conflict with alirocumab.

Practical Dosing Guidance

Because no interaction exists, patients do not need to separate doses of vitamin D and alirocumab by time. Alirocumab is injected subcutaneously every two weeks (75 mg or 150 mg) or monthly (300 mg), while vitamin D is taken orally. The routes of administration are different, and no absorption competition occurs.

Choosing a Vitamin D Dose

The Endocrine Society's 2024 Clinical Practice Guideline recommends that adults aged 19 to 74 with 25(OH)D levels below 30 ng/mL consider supplementation with 1,500 to 2,000 IU/day of vitamin D3 [8]. Patients at higher risk of deficiency (BMI ≥30, malabsorption syndromes, chronic kidney disease) may require 3,000 to 6,000 IU/day under medical supervision.

Timing Considerations

Take vitamin D with a fat-containing meal to improve absorption. A crossover study (N=17) published in the Journal of the Academy of Nutrition and Dietetics showed that taking vitamin D3 with the largest meal of the day increased serum 25(OH)D by approximately 50% compared to taking it on an empty stomach [9]. This is unrelated to alirocumab timing; the injection can be administered at any time regardless of meals.

Statin Co-Use and Vitamin D

Most alirocumab patients also take a statin. A systematic review and meta-analysis of 14 studies found that statin use was associated with increased serum 25(OH)D levels in some populations, possibly through enhanced hepatic hydroxylation [10]. The clinical significance is debatable, but the finding suggests that the statin-alirocumab-vitamin D triad does not create additive risk. If anything, statin co-therapy may modestly improve vitamin D status.

Monitoring Recommendations

Even without an interaction, monitoring vitamin D levels is good practice in the ASCVD population.

Baseline and Annual 25(OH)D Testing

Check 25(OH)D at the time alirocumab is initiated. If levels fall below 20 ng/mL, start supplementation and recheck at 8 to 12 weeks to confirm repletion. Once stable, annual monitoring is sufficient. The American Association of Clinical Endocrinology (AACE) lists 25(OH)D testing as appropriate for patients with cardiovascular disease, obesity, or chronic kidney disease [11].

Calcium and PTH Considerations

Vitamin D regulates calcium absorption and parathyroid hormone (PTH) secretion. Patients taking calcium supplements alongside vitamin D and alirocumab should ensure total daily calcium stays below 2,500 mg (the tolerable upper intake for adults aged 19 to 50 per the National Institutes of Health Office of Dietary Supplements) [12]. Hypercalcemia is not a known risk of alirocumab, but it is a known risk of excessive vitamin D and calcium co-supplementation.

Liver and Lipid Panel Monitoring

Standard alirocumab follow-up includes a fasting lipid panel 4 to 8 weeks after initiation and every 12 weeks thereafter until the target LDL-C is reached. There is no evidence that vitamin D supplementation alters lipid panel results in a way that confounds alirocumab dose titration. The ODYSSEY OUTCOMES trial (N=18,924) used standard lipid monitoring without excluding vitamin D users [13].

When to Reconsider the Combination

The combination of alirocumab and vitamin D is safe for the vast majority of patients. A few situations warrant a closer look, not because of a direct interaction, but because of overlapping clinical complexity.

Severe Chronic Kidney Disease (eGFR <30)

Patients with stage 4 or 5 CKD have impaired renal 1-alpha-hydroxylation of 25(OH)D. These patients often require calcitriol or activated vitamin D analogs rather than cholecalciferol. Alirocumab has been studied in CKD populations without unique safety signals, but mineral and bone disorder management should involve nephrology input.

Granulomatous Diseases (Sarcoidosis, Tuberculosis)

Activated macrophages in granulomatous tissue express CYP27B1 and can convert 25(OH)D to 1,25(OH)₂D in an unregulated manner, raising the risk of hypercalcemia. Patients with sarcoidosis taking vitamin D need closer calcium monitoring. This is independent of alirocumab but relevant when managing the full medication list.

High-Dose Vitamin D Regimens (Over 10,000 IU/day)

A systematic review in the Annals of Internal Medicine confirmed that vitamin D doses exceeding 10,000 IU/day chronically raise the risk of hypercalcemia and nephrocalcinosis [14]. The concern is not an alirocumab interaction. It is vitamin D toxicity as a standalone risk. Keep daily intake below 4,000 IU unless lab-guided escalation is warranted.

What to Tell Your Prescriber

Bring a complete supplement list to every alirocumab appointment. While vitamin D does not interact with the drug, the prescriber needs the full picture to manage bone health, kidney function, and cardiovascular risk in an integrated way. Dr. Robert Eckel, past president of the American Heart Association, has stated: "Supplement disclosure is as important as medication reconciliation. We cannot manage cardiovascular risk in a vacuum."

If you are already taking both vitamin D and Praluent, there is no reason to stop either one. No dose adjustment is needed. No timing separation is required.

Patients starting alirocumab who are vitamin D deficient should begin supplementation promptly. A Lancet Diabetes & Endocrinology review noted that correcting vitamin D deficiency may improve musculoskeletal symptoms that overlap with statin-related myalgia, a common reason patients are escalated to PCSK9 inhibitors in the first place [15].

The 2019 ACC/AHA guideline on primary prevention of cardiovascular disease recommends assessing and managing modifiable risk factors comprehensively, which includes nutritional deficiencies [16]. Alirocumab addresses LDL-C. Vitamin D addresses bone and mineral health. The two therapies target different systems with no mechanistic overlap. Take both as directed by your clinician.